Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17)

Phase II Clinical Trial

A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer
Trial Number: 05609578
Trial Status: Call Proj Mgr

Learn more about this clinical trial.

Participating Locations